TAFALGIE THERAPEUTICS
EIC Accelerator Winner From 2023
The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
France
The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance